CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 16 enrolled
Drug / intervention
Mepolizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04965636
NCT04965636Phase 3Completed
CompareCT.gov

A Phase 3, 52-week, Open-label, Single Arm Study to Investigate the Efficacy and Safety of Mepolizumab SC in Participants Aged 6 to 17 Years With Hypereosinophilic Syndrome

GlaxoSmithKline·interventional·Posted Jul 16, 2021·Updated May 4, 2026

In Brief

A Phase 3 clinical trial evaluating Mepolizumab for Hypereosinophilic Syndrome. Completed, enrolled 16 participants across 1 site.

Detailed Summary

The purpose of this study is to investigate the efficacy and safety of mepolizumab in children and adolescents with hypereosinophilic syndrome (HES) who are receiving standard of care (SoC) therapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypereosinophilic Syndrome
CountriesArgentina
Collaborators--

Timeline

Phase 3CompletedFinished
20222023202420252026
First PostedJul 16, 2021
Enrollment StartJul 14, 2022
Primary CompletionOct 28, 2025
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 5.0 years ago

Interventions

Mepolizumabdrug

Mepolizumab was provided in pre-filled safety syringe